Related content

Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: A phase II trial

By Ta-Chung Chao   Zyting Chu   Ling-Ming Tseng   Tzeon-Jye Chiou   Ruey-Kuen Hsieh   Wei-Shu Wang   Chueh-Chuan Yen   Muh-Hwa Yang   Liang-Tsai Hsiao   Jin-Hwang Liu   Po-Min Chen  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 171-177

Springer Publishing Company

Access to resources Recommend Favorite

Rapid HPLC method for the determination of paclitaxel in pharmaceutical forms without separation

By Badea I.   Ciutaru D.   Lazar L.   Nicolescu D.   Tudose A.  

Journal of Pharmaceutical and Biomedical Analysis, Vol. 34, Iss. 3, 2004-02 ,pp. : 501-507

Elsevier

Access to resources Recommend Favorite

Effect of Unpurified Cremophor EL on the Solution Stability of Paclitaxel

By Gogate Uday   Schwartz Philip   Agharkar Shreeram  

Pharmaceutical Development and Technology, Vol. 14, Iss. 1, 2009-01 ,pp. : 1-8

Informa Healthcare

Access to resources Recommend Favorite

A Validated High Performance Liquid Chromatographic (HPLC) Assay for Nitazoxanide in Bulk and in Pharmaceutical Formulations

By  

Current Pharmaceutical Analysis, Vol. 10, Iss. 3, 2014-08 ,pp. : 215-222

Bentham Science Publishers

Access to resources Recommend Favorite

Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples

By  

Current Pharmaceutical Analysis, Vol. 10, Iss. 3, 2014-08 ,pp. : 185-192

Bentham Science Publishers

Access to resources Recommend Favorite